Literature DB >> 20238303

Targeting the renin angiotensin system for remission/regression of chronic kidney disease.

Daniela Macconi1.   

Abstract

In the last few years great progress has been made in the search for the cellular and molecular mechanisms of chronic kidney disease and its progression to end-stage renal failure. The possibility of remission/regression of chronic nephropathy has become a reality for some patients on therapy based on renin-angiotensin system blockade - an example of how a public health concern can be successfully addressed by translational medicine. This review describes experimental and clinical investigations documenting the advances achieved in the management of chronic kidney diseases by targeting angiotensin II.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20238303     DOI： 10.14670/HH-25.655

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN： 0213-3911            Impact factor:   2.303


  8 in total

1.  Renoprotective effects of the novel prostaglandin EP4 receptor-selective antagonist ASP7657 in 5/6 nephrectomized chronic kidney disease rats.

Authors:  Kazuhiko Mizukami; Hiroyuki Yoshida; Eisuke Nozawa; Koichi Wada; Tohru Ugawa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-12-15       Impact factor: 3.000

2.  MicroRNA-324-3p promotes renal fibrosis and is a target of ACE inhibition.

Authors:  Daniela Macconi; Susanna Tomasoni; Paola Romagnani; Piera Trionfini; Fabio Sangalli; Benedetta Mazzinghi; Paola Rizzo; Elena Lazzeri; Mauro Abbate; Giuseppe Remuzzi; Ariela Benigni
Journal:  J Am Soc Nephrol       Date:  2012-07-19       Impact factor: 10.121

Review 3.  Key fibrogenic mediators: old players. Renin-angiotensin system.

Authors:  Daniela Macconi; Giuseppe Remuzzi; Ariela Benigni
Journal:  Kidney Int Suppl (2011)       Date:  2014-11

4.  Treatment with enalapril and not diltiazem ameliorated progression of chronic kidney disease in rats, and normalized renal AT1 receptor expression as measured with PET imaging.

Authors:  Basma Ismail; Rob A deKemp; Etienne Croteau; Tayebeh Hadizad; Kevin D Burns; Rob S Beanlands; Jean N DaSilva
Journal:  PLoS One       Date:  2017-05-19       Impact factor: 3.240

5.  The RenTg mice: a powerful tool to study renin-dependent chronic kidney disease.

Authors:  Anne-Cecile Huby; Panagiotis Kavvadas; Carlo Alfieri; Ahmed Abed; Julie Toubas; Maria-Pia Rastaldi; Jean-Claude Dussaule; Christos Chatziantoniou; Christos E Chadjichristos
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

6.  Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats.

Authors:  Petr Kujal; Vera Čertíková Chábová; Petra Škaroupková; Zuzana Husková; Zdena Vernerová; Herbert J Kramer; Agnieszka Walkowska; Elzbieta Kompanowska-Jezierska; Janusz Sadowski; Kento Kitada; Akira Nishiyama; Sung H Hwang; Bruce D Hammock; John D Imig; Ludek Červenka
Journal:  Clin Exp Pharmacol Physiol       Date:  2014-03       Impact factor: 2.557

7.  The Effect of Chinese rhubarb, Rheum officinale, with and without benazepril on the progression of naturally occurring chronic kidney disease in cats.

Authors:  A S Hanzlicek; C J Roof; M W Sanderson; G F Grauer
Journal:  J Vet Intern Med       Date:  2014-04-28       Impact factor: 3.333

8.  Chronic treatment with the (iso-)glutaminyl cyclase inhibitor PQ529 is a novel and effective approach for glomerulonephritis in chronic kidney disease.

Authors:  Naotoshi Kanemitsu; Fumiko Kiyonaga; Kazuhiko Mizukami; Kyoichi Maeno; Takashi Nishikubo; Hiroyuki Yoshida; Hiroyuki Ito
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-03-29       Impact factor: 3.000
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.